Scilex Holding Company SCLX PHARMA
Company Overview
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Recent Developments
- Dec 2025 Revenue of $30.25M (-46.5% YoY); net profit $-374.05M.
- Trailing 12 Months Year-on-year growth — revenue -22.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.13% |
| 1 Year: | -22.80% |
Stock Price Performance
| 1 Year: | -58.93% |
| 6 Months: | +0.51% |
| 3 Months: | +24.81% |
| 1 Month: | -22.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 71.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SCLX Scilex Holding Company PHARMA | 5.37 | -0.11 | $37.78M | 0.00% | - | - | 5.13% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 6.81M | 7.93M | 11.38M | 10.58M | 12.58M | 10.12M | 10.88M | 16.37M | 14.44M | 5.00M | 9.90M | 10.56M | 8.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.70M | - | - | 25.70M |
| Operating Income | -856 | -165.16K | -172.14K | -283.35K | -8.81M | -11.47M | -10.62M | -25.47M | -22.81M | -38.80M | -19.48M | -15.62M | -19.92M | -27.90M | -20.51M | -186.51M | -32.17M |
| Net Income | -856 | 1.33M | -233.75K | -1.44M | -9.14M | -17.84M | 21.50M | -30.75M | -26.65M | -35.53M | -24.38M | -37.58M | -4.39M | -26.08M | -44.05M | -257.82M | -45.65M |
| Diluted EPS | 0.00 | 0.09 | -0.01 | -0.08 | -0.07 | -0.13 | 0.16 | -0.22 | -0.19 | -0.63 | -8.33 | -7.67 | -0.58 | -2.26 | -7.42 | -22.17 | -6.28 |
| R&D Expense | - | - | - | - | 2.63M | 2.59M | 1.24M | 2.74M | 3.20M | 4.07M | 3.11M | 2.00M | 2.35M | 2.46M | 6.19M | 3.90M | 3.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 23.56M | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Gross Profit | - | - | - | - | 167.40M | 125.80M |
| Operating Income | -35.26M | -35.84M | -50.63M | -105.43M | -83.40M | -346.01M |
| Net Income | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M | -374.05M |
| Diluted EPS | -0.36 | -0.67 | -0.17 | -1.28 | -8.05 | -36.48 |
| R&D Expense | 9.96M | 9.20M | 9.05M | 12.75M | 9.64M | 20.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 199.48K | 77.93M | 86.53M | 101.31M | 92.95M | 364.98M |
| Total Equity | -90.03M | 18.72K | -223.88M | 36.24M | -172.94M | -192.64M | -207.78M |
| Cash & Equivalents | - | 30.51K | 4.34M | 2.18M | 3.92M | 3.27M | 4.96M |
| Long Term Debt | - | - | 72.04M | 0 | - | - | - |
| Total Liabilities | - | 180.76K | 301.81M | 50.29M | 274.25M | 285.59M | 576.73M |
| Current Liabilities | - | 180.76K | 169.42M | 44.84M | 250.38M | 259.63M | 483.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.46M | -28.66M | -21.26M | -20.71M | 19.35M | 3.82M |
| Investing Cash Flow | -25.00K | 0 | -2.07M | -330.00K | -2.67M | 4.08M |
| Financing Cash Flow | -19.17M | 28.16M | 21.17M | 23.58M | -18.13M | -5.46M |
| Capital Expenditure | -25.00K | -0 | -7.00K | -30.00K | -0 | -133.00K |
| Free Cash Flow | -31.49M | -28.66M | -21.27M | -20.74M | 19.35M | 3.68M |
| Dividends Paid | - | - | - | 8.65M | 8.65M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 295.8% | 415.8% |
| Operating Margin % | -149.7% | -114.4% | -133.1% | -225.6% | -147.4% | -1,143.7% |
| Net Margin % | -201.7% | -282.4% | -61.4% | -244.6% | -128.7% | -1,236.4% |
| ROE % | -253,786.6% | 39.5% | -64.5% | 66.1% | 37.8% | 180.0% |
| ROCE % | -188,303.8% | 39.2% | -121.5% | 70.7% | 50.0% | 291.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.55% | 301.29K | $1.52M |
| 2 | Blackrock Inc. | 1.29% | 109.42K | $551.46K |
| 3 | Vanguard Fiduciary Trust Co | 0.54% | 45.82K | $230.94K |
| 4 | Jacobs Levy Equity Management, Inc. | 0.48% | 41.16K | $207.46K |
| 5 | State Street Corporation | 0.42% | 35.38K | $178.29K |
| 6 | UBS Group AG | 0.39% | 33.38K | $168.22K |
| 7 | Renaissance Technologies, LLC | 0.39% | 33.06K | $166.64K |
| 8 | Citadel Advisors Llc | 0.32% | 27.50K | $138.58K |
| 9 | Price (T.Rowe) Associates Inc | 0.25% | 20.92K | $105.44K |
| 10 | Ashton Thomas Private Wealth, LLC | 0.22% | 18.48K | $93.15K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCLX
Federal Court Grants Motion to Stay Proceedings in Scilex v. Wade et al.
The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. and Marc Wade today announced that the U.S. District Court has granted their motion to compel arbitration and stay all court proceedings in California brought…
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non…
Scilex, Vera Therapeutics rise premarket; Strategy gains
Investing.com - U.S. stock index futures edged higher on Monday as investors returned from a long holiday weekend, with technology shares leading gains.
Scilex Shares Jump After Securing $100 Million Strategic Investment Proposal (SCLX)
Binding Term Sheet Supports Growth PlansScilex Holding Company (NASDAQ:SCLX) shares climbed 7% on Monday after the company announced it had signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based p…
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain managemen…
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain managemen…
SCLX — Frequently Asked Questions
What is the current share price of Scilex Holding Company (SCLX)?
As of 2026-09-19 21:16 PDT, Scilex Holding Company (SCLX) trades at $5.37 on NasdaqCM. Its 52-week range is $3.69 to $18.68.
What is the market capitalisation of SCLX?
Scilex Holding Company (SCLX) has a market capitalisation of $37.78M on NasdaqCM.
What is the P/E ratio of SCLX?
SCLX trades at a trailing price-to-earnings (P/E) ratio of -0.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.11.
Is SCLX a good stock to buy?
This page provides a data-driven analysis of Scilex Holding Company (SCLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.